Technical Lead Architect - CTI MD Tech (GRA/GSC)
Eli Lilly and Company16 days ago
Bengaluru, IndiaStaff+
Responsibilities
- Transform regulatory and scientific communications processes into AI-driven, agentic workflows with human-in-the-loop checkpoints.
- Define and own the AI, Generative AI, and Agentic AI strategy across the GRA/GSC portfolio.
- Establish governance, operating models, architectural patterns, and reference models for secure AI and agentic workflows.
- Own the portfolio technology strategy, roadmap, investment planning, and modernization agenda.
- Partner with business and portfolio leadership on capability planning, prioritization, and technology opportunities.
- Evaluate emerging technologies and lead portfolio rationalization to consolidate, simplify, and modernize systems.
- Ensure solutions are scalable, secure, resilient, compliant, and aligned with enterprise architecture standards.
- Mentor technical leaders, architects, and engineering teams.
Requirements
- Proven experience developing and executing enterprise technology strategies.
- Demonstrated success leading large-scale digital transformation initiatives, including AI-driven and agentic automation.
- Experience driving technology investments, portfolio modernization, and architecture governance.
- Experience leading through ambiguity, complexity, and organizational transformation.
- Experience in both Global Regulatory Affairs and Scientific Communications.
- Familiarity with Regulatory Content and Submission Management, Veeva RIM, and regulatory platforms.
- Experience with document and content management ecosystems.
- Background in pharma and GxP-regulated environments.
Tech Stack
Categories
About Eli Lilly and Company
Eli Lilly and Company researches, develops, manufactures, and markets prescription medicines and biologics for patients, sold through healthcare providers, pharmacies, and payers. Core therapeutic areas include diabetes, oncology, immunology, neuroscience, and obesity. Founded in 1876 and headquartered in Indianapolis, it is a public company (NYSE: LLY) with global operations and is building a new advanced manufacturing site for gene therapy and other modalities in Lebanon, Indiana.